North Staffordshire Joint Formulary Formulary

This is a Specialised Drug which would not be routinely commissioned by CCGs for Endocrinology: non-malignant conditions. This would go through CCGs Individual Funding Request (IFR).

NICE TA121: Carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma

NICE TA23: Guidance on the use of temozolomide for the treatment of recurrent malignant glioma (brain cancer)

Tisagenlecleucel (Kymriah^®)

Formulary

Restriction: In line with NICE guideline only

NICE TA 567: Tisagenlecleucel for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic therapies

NICE TA554: Tisagenlecleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people aged up to 25 years

Tivozanib (Fotivda^®)

Formulary

Restriction: In line with NICE Guidance only

NICE TA512: Tivozanib for treating advanced renal cell carcinoma

Topotecan (Hycamtin^®)

Formulary

Restriction: In line with NICE Guidance only

NICE TA183: Topotecan for the treatment of recurrent and stage IVB cervical cancer

NICE TA184:Topotecan for the treatment of relapsed small-cell lung cancer

NICE TA389 - Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer

Trabectedin (Yondelis^®)

Formulary

Restriction: In line with NICE Guidance only

NICE TA185: Trabectedin for the treatment of advanced soft tissue sarcoma

NICE TA389 - Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer

Trametinib (Mekinist^®)

Formulary

Restriction: In line with NICE Guidance only

NICE TA396: Trametinib in combination with dabrafenib for treating unresectable or metastatic melanoma

NICE TA544; Dabrafenib with trametinib for adjuvant treatment of resected BRAF V600 mutation-positive melanoma

Trastuzumab

Formulary

Restriction: In line with NICE Guidance only

NICE NG101: Early and locally advanced breast cancer: diagnosis and management

NICE TA34: Guidance on the use of trastuzumab for the treatment of advanced breast cancer

NICE TA208: Trastuzumab for the treatment of HER2-positive metastatic gastric cancer

NICE TA509: Pertuzumab with trastuzumab and docetaxel for treating HER2-positive breast cancer

Trastuzumab emtansine

Formulary

Restriction: In line with NICE Guidance only

NICE TA458: Trastuzumab emtansine for treating HER2-positive advanced breast cancer after trastuzumab and a taxane

NICE TA632: Trastuzumab emtansine for adjuvant treatment of HER2-positive early breast cancer

Trifluridine-tipiracil
(Lonsurf^®)

Formulary

Restriction: In line with NICE Guidance only

NICE TA405: Trifluridine–tipiracil for previously treated metastatic colorectal cancer

Vemurafenib (Zelboraf^®)

Formulary

Restriction: In line with NICE Guidance only

Drug rash with eosinophilia and systemic symptoms (DRESS syndrome)

MHRA/CHM advice (November 2015): Risk of potentiation of radiation toxicity

NICE TA269: Vemurafenib for treating locally advanced or metastatic BRAF V600 mutation‑positive malignant melanoma

Venetoclax (Venclyxto^®)

Formulary

Restriction: In line with NICE Guidance only

NICE TA487: Venetoclax for treating chronic lymphocytic leukaemia

NICE TA561: Venetoclax with rituximab for previously treated chronic lymphocytic leukaemia

....

Key

	Notes
	Section Title (top level)
	Section Title (sub level)
	First Choice item
	Non Formulary section
	Restricted Drug
	Unlicensed
	Display tracking information
	Link to adult BNF
	Link to children's BNF
	Link to SPCs
	Scottish Medicines Consortium

	Cytotoxic Drug
	Controlled Drug
	High Cost Medicine
	Cancer Drugs Fund
	NHS England
	Homecare
	CCG
	High Cost Drug Approval System

Traffic Light Status Information

Status	Description
	Medicines that can only be prescribed within Secondary Care. Examples of medicines which fall into this category are: Certain new medicines and new indications for older medicines where there is at present no experience of use in Primary Care. Medicines or dressings not available or prescribable in Primary Care. Where a medicine has been classified as Amber E, but an approved shared-care guideline is not yet available
	Medicines which can be prescribed within Secondary Care, but are only suitable for prescribing in Primary Care after specialist referral. There is no need for approved shared care guidelines for medicines in this category. This replaces Amber 2 on the North Staffs Formulary.
	Medicines which can be prescribed within Secondary Care, but are only considered suitable for prescribing in Primary Care under an approved shared-care agreement (ESCA) or Rationale for Initiation, Continuation and Discontinuation (RICaD). This replaces Amber 1 on the North Staffs Formulary
	Medicines which can be prescribed in either Primary or Secondary Care.
	These medicines have been reviewed by the New Medicines Committee and the Area Prescribing Committee and found not to be suitable for inclusion in the Joint Formulary. Inadequate or weak evidence for efficacy No clearly defined local need Lack of long term safety data No perceived benefit over established formulary alternatives Prescribers can consider these medicines where formulary alternatives are unsuitable, ineffective or not tolerated.